跳至主要内容
临床试验/NCT06205979
NCT06205979招募中早期 1 期

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Sohag University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年12月12日最近更新:
适应症
相关药物

试验速览

阶段
早期 1 期
状态
招募中
入组人数
50
试验地点
1
主要终点
change in the best corrected visual acuity in meters

研究概览

简要总结

Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR . Retinal oedema is responsible for retinal micro-structural alterations, retinal atrophy of photoreceptors and ganglion cell disorders . In addition, it might be considered consensual that the best improvements in VA could be accomplished when retinal oedema is managed. In the context of a chronic and progressive disease, DME has to be faced as a state to control as effectively and rapidly as possible . Vascular endothelial growth factor (VEGF) is a protein that promotes the growth of new blood vessels. It also makes the blood vessels more leaky. Anti- VEGF medicines stop the growth of these new blood vessels. This prevents damage to the retinal light receptors and loss of central vision. The DME treatment has been shifted from the laser photocoagulation to anti-VEGF therapy . The advantages of anti-VEGF therapy in decreasing DME and improving patient's vision have been reported in many studies . Ranibizumab, in addition to aflibercept, have been reported as the first line therapies among the other anti-VEGF . There are several data demonstrating the efficiency of ranibizumab in treatment of patients with DME . On the other hand, there are studies that revealed poor response of some patients to anti-VEGF therapies even after 3 or more injections Non-modifiable risk factors for diabetic retinopathy are gender and DM duration.

Modifiable risk factors contributing to the development of diabetic retinopathy are elevated blood sugar levels, blood pressure, and dyslipidemia which is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol, (LDL-C), triglycerides, and high-density lipoprotein (HDL). This condition can result from diet, tobacco exposure, or genetic . Hard exudates are thought to be induced by the leakage of lipids from dysfunctional retinal capillaries . Therefore, theses were formulated that higher levels of total cholesterol, LDL-C and triglycerides could be considered biomarkers of the development of hard exudates in DM patients . Aim of the work

  • Correlate between dyslipidemia and the response of patients with diabetic macular oedema to intravitreal anti-VEGF injection

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with type II DM and center involving DME with central foveal thickness more than 280 um.

排除标准

  • Evidence of macular ischemia
  • Evidence of macular traction
  • Previous intravitreal injections
  • Previous macular laser therapy
  • Previous pars plana vitrectomy

结局指标

主要结局

change in the best corrected visual acuity in meters

时间窗: 2 months

measure of the ability of the eye to distinguish shapes and the details of objects at a given distance with the help of corrective lenses

change in the retina and macula measurements by Optical coherence tomography (OCT)

时间窗: 2 months

assess the state of the retina and macula by measuring : * Average Thickness in (μm)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ola Gamal Amin

resident of ophthalmology at el Helal hospital

Sohag University

研究点 (1)

Loading locations...

相似试验